National Action Plan development support tools

Transcription

1 National Action Plan development support tools Sample Checklist This checklist was developed to be used by multidisciplinary teams in countries to assist with the development of their national action plan (NAP) on AMR or assist with reviewing and updating existing national action plans. Existing National Action Plan **If there is no National Action Plan please SKIP Questions 1-4 and go directly to Question 5 1. There is already a national action plan (NAP) on AMR The plan is based on a national strategy on AMR The plan is officially approved by the government and published with open access A dedicated budget is allocated for implementing the activities in the plan The plan is aligned to a national health plan and other human, animal, plant and environmental health strategies and food safety strategies e.g. infection prevention and control, patient safety, environmental health, animal health and welfare,plant production, regulation of use of antimicrobial agents 1.5. The plan is updated regularly. e.g. within at least 5 years 1.6. A national AMR report on implementation of the NAP is published regularly with open access. e.g. within at least 5 years 1

2 2. The national action plan reflects the principles outlined in the global action plan. **If there is no National Action Plan please SKIP Questions 1-4 and go directly to Question Whole-of-society engagement including a one health approach: all sectors in addition to human health (e.g. animal health, plants, food, environment, economic development, education) should be engaged in the preparation and implementation of the action plan Prevention first Prevention of infection can be cost-effective and implemented in all settings and sectors, even where resources are limited Access Both equitable access to and appropriate use of existing and new antimicrobial agents are required Sustainability Long-term technical and financial investment is needed for implementation of the national plan Incremental targets The plan will be implemented in a stepwise manner to meet both local needs and global priorities 2.6. Meets intergovernmental standards where relevant e.g. Codex, OIE Code 2

3 3. The national action plan addresses the five strategic objectives of the global action plan 3.1. Strategic objective 1 Improve awareness and understanding of AMR through effective communication, education and training Strategic objective 2 Strengthen the knowledge and evidence base through surveillance and research Strategic objective 3 Reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures Strategic objective 4 Optimize the use of antimicrobial agents in human animal and plant health Strategic objective 5 Develop the economic case for sustainable investment, taking into account the needs of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions. 3

4 4. The national action plan includes key components of a comprehensive plan Strategic (core) plan Explains and specifies goals, objectives and strategic interventions that match the situation analysis and linked to the global action plan strategic objectives Operational plan (including technical assistance planning) Provides detailed information on each activity and milestone for the coming 1 or 2 years of the period covered by the plan 4.3. Monitoring and evaluation plan Refers to each operational objective and each strategic intervention defined in the core plan and includes indicators to assess achievement against a baseline and data collection method 4.4. Budget plan Establishes the costs of each activity in each year of the plan and identifies both funding and funding gaps for each year and for the overall period covered by the plan 4

5 Governance and multisectoral One Health coordination 5. There is national coordination on activities in the country among AMR focal points, with defined roles and responsibilities, including to: 5.1. Facilitate formation of a national multisectoral coordinating group (NMCG) 5.2. Facilitate and coordinate development of the national AMR action plan through the NMCG Facilitate and oversee implementation, monitoring and evaluation of the AMR action plan through the NMCG Ensure regular data collection and information-sharing among all relevant sectors and stakeholders by facilitating effective communication and coordination between the members of the NMCG and with international partners 5

6 6. A national multisectoral coordinating group (NMCG) is established The NMCG has strong political support. ideally, created by regulation and overseen by the prime minister s office or equivalent to ensure inter- Ministry cooperation 6.2. The NMCG has authority to act. Sufficient authority is assigned to enable NMCG recommendations and plans to be implemented The NMCG is accountable to the government The NMCG has dedicated funds The NMCG has a secretariat with dedicated personnel and funds for administrative costs The NMCG is supported by technical experts including human and animal health, plant, food, and environmental expertise. 6

8 8. Technical working groups are created as needed. Members may represent the following areas 2 (please adapt this list to your country s situation). Human health Animal health, welfare, and production including fisheries Food safety and security, including food production and processing Plants and agriculture Environment, including water and sewage Technical disciplines e.g. Infectious diseases, pharmacy, IPC, epidemiology, Others 2 This is a non-exhaustive generic list; the specialities listed and their equivalents need to be adapted to each country s situation. Other specialities and technical areas could be added to ensure that all key sectors are represented and expertise is available. 8

12 12. Education and information on AMR provided to the general public Include antimicrobial use and resistance in school curricula Provide accurate, relevant information on AMR to public 13. AMR is recognized as a national priority Use effective mechanisms to ensure inter-ministerial collaboration and commitment Promote and support establishment of public-private, multisectoral ( One Health ) coalitions to address AMR at local or national level Promote and support participation in public-private, multisectoral ( One Health ) coalitions to address AMR at regional and global level 12

13 GAP Strategic Objective 2. Strengthen the knowledge and evidence base through surveillance and research. 14. National AMR surveillance and use monitoring systems exist or are planned, comprising: Surveillance of AMR in isolates from humans e.g. in health care facilities and the community Surveillance of AMR in isolates from animals e.g. livestock, aquatic animals, companion animals Surveillance of AMR in isolates from food Surveillance of AMR in isolates from plants Surveillance of AMR in isolates from the environment e.g. sewage, water Monitoring of use of antimicrobial agents in humans e.g. in health care facilities and the community Monitoring of use of antimicrobial agents in animals (including the OIE collection of data) Monitoring of the use of antimicrobial agents in plants Special studies to provide information not covered by routine surveillance to provide supplementary information on, for example, AMR burden, effects of interventions, potential causes and drivers of AMR emergence, AMR in wildlife 13

14 15. Data on the extent and impact of AMR are available Incidence and prevalence of AMR in humans, animals, plants, food, and environment Human morbidity, mortality and other health outcomes in relation to AMR Data on economic impact of AMR in humans, animals, plants, food, and the environment 14

15 16. A national AMR surveillance and antimicrobial use (AMU) report (within the past 5 years) publicly available, including AMR in isolates from humans AMR in isolates from animals AMR in isolates from plants AMR in isolates from food AMR in isolates from the environment Antimicrobial use in humans Antimicrobial use in animals Antimicrobial use in plants 15

16 17. A national mechanism coordinates the different national AMR surveillance and antimicrobial use (AMU) monitoring systems Defines the objectives of the national surveillance systems based on intergovernmental standards Reviews and coordinates dissemination of existing national AMR surveillance and AMU monitoring protocols (and coordinates protocol development as needed) Coordinates AMR data collection, analysis, reporting and sharing across the human health, animal health, food, plant and environmental sectors both nationally and with international and global networks Monitors data on the use of antimicrobial agents in humans, animals, and plants, and continuously evaluates the national surveillance systems Links and coordinates AMR surveillance in the human health, animal health, plant, food, and environment sectors 16

17 18. One or more national reference laboratories have been nominated for surveillance of AMR, to Accurately confirm diagnoses including verification of results (detection or confirmation of unusual or new resistance patterns) reported by participating laboratories, detection of specific microbial markers and investigation of atypical samples Develop, maintain and share relevant reference material including reference laboratory strains and cultures, clinical isolates, sera, genetic material Serve as a resource and coordination point for expertise and for sharing information and advice with relevant stakeholders including technical advice on methods and procedures, scientific support and advice on the interpretation and relevance of laboratory findings Engage in collaboration and research including participation in and contribution to international and global surveillance and internationally relevant projects and initiatives, including research and development activities Provide guidance and technical support for the management of quality, including participation in external quality assurance schemes Liaise with the national AMR coordinating mechanism 17

18 19. A national research agenda implemented, including Social science and behavioural studies and other research to support achievement of the global objectives including studies to promote responsible use of antimicrobial agents and effective antimicrobial stewardship programmes in human health, animal health, and plant health Research to develop new treatments, diagnostic tools, vaccines and other interventions in humans, animal, and plants related to infectious diseases involving promotion of partnerships between research institutions at national, regional and international level Research to identify alternatives to non-therapeutic uses of antimicrobial agents in animals and plants including their use for growth promotion and crop protection Economic research, including development of models to assess the cost of AMR and the costs and benefits of the national action plan for the human health, animal health, food, plant and environment sectors 18

19 GAP Strategic Objective 3. Reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures. 20. Infection prevention and control (IPC) programmes introduced across the spectrum of human health settings, including A national programme for IPC in health care IPC programmes in hospitals IPC programmes in long-term care and outpatient and community health settings IPC programmes in congregate settings e.g. correctional facilities and military barracks, to homeless shelters, refugee camps, dormitories and nursing homes 19

20 21. Intergovernmental standards and guidelines related to infection prevention and control (IPC) implemented in The animal health sector The plant sector The food sector The environment sector 20

21 22. The infection prevention and control (IPC) programmes for human health adapted to local conditions and include the following essential (core) components: A formal organizational structure to facilitate proper development and management of IPC policies and strategies Infection control guidelines and policies, including strategies and guidelines for AMR Training of health care providers in the principles and practice of IPC Appropriate environment (including facilities and environmental designs) for application of IPC principles and practices Laboratory and diagnostic support for prescribing antimicrobial agents and accurate, timely detection of infections caused by resistant pathogens Surveillance systems to collect and report data on health care-associated infections and the susceptibility of the microorganisms to antimicrobial agents to enable rapid detection and containment of emerging drugresistant microorganisms Monitoring and evaluation framework to monitor implementation and enable timely adaptation of IPC strategies Links with public health, other services and societal bodies to facilitate communication 21

22 23. Training and education in hygiene and IPC are core (mandatory) components of education, training, and development Human health Animal health Plant production Food chain Environment Hygiene and IPC included in undergraduate curricula Hygiene and IPC included in continuing education programmes Hygiene and IPC included in education/training provided outside formal academic settings 22

23 24. Hygiene and infection prevention and control (IPC) measures are planned outside health settings Promotion of personal hygiene by social mobilization and behavioural change activities at home, at work and in social settings Prevention of infections in humans transmitted through sex or drug injection Provision of safe, sufficient drinking-water and adequate sanitation Strengthening of vaccination programmes to reduce the burden of infectious diseases Promotion of good hygiene practices along the food chain Good practices in place in animal health, welfare and production including vaccination Good practices in place in the plant production Good practices in place in the environment sector 23

24 GAP Strategic Objective 4. Optimize the use of antimicrobial agents in human and animal health 25. Effective, enforceable regulation and governance are planned for licensing, distribution, and quality assurance of antimicrobial agents in human, animals, and plants There is a national human drug regulatory authority There is a national animal drug regulatory authority There are regulations in place for antimicrobial agents used in the plant sector Marketing authorization is given following international standards and guidelines to ensure that antimicrobial agents are quality assured, safe and effective Mechanisms or requirements are in place for detecting and combating counterfeit antimicrobial agents Promotional practices by industry are regulated and controlled There is a quality management system for the antimicrobial agents supply chain (e.g. for storage, transportation, expiry date) There is a regulatory framework for preservation of new antimicrobial agents Economic incentives that encourage inappropriate use of antimicrobial agents are being identified and addressed in all sectors Economic incentives to optimize use of antimicrobial agents are being introduced in all sectors 24

25 26. Purchasing and prescribing of antimicrobial agents guided and supported by A national essential medicine list guided by the WHO Model Lists of Essential Medicines Institutional essential medicine lists Reimbursement lists for human health Standard treatment guidelines for use of antimicrobial agents in humans Standard treatment guidelines for use of antimicrobial agents in animals Standard treatment guidelines for use of antimicrobial agents in plants Medical or veterinary supervision Standard treatment recommendations are developed for animals Standard treatment recommendations are developed for plants Policies that promote the prudent and responsible use of antimicrobial agents based on existing intergovernmental standards and guidelines 25

26 27. Policies on use of antimicrobial agents in animals and plants prepared, including Policies on the use of critically important antimicrobials Policies on phasing out use of antimicrobials for animal growth promotion and crop protection in the absence of risk analyses Policies on reduction in nontherapeutic use of antimicrobial agents in animal health 26

27 28. Antimicrobial stewardship programmes set up for human health at national and local levels, including A formal multidisciplinary organizational structure responsible for antimicrobial stewardship Qualified human resources An antimicrobial stewardship team including an antibiotic adviser or leader, an antimicrobial pharmacist, IPC professional, microbiologist Facility-specific treatment recommendations Review of appropriateness of antimicrobial agents h after administration (post-prescription review) Direct communication of the results of audits and reviews to all sectors using antimicrobial agents 27

28 GAP Strategic Objective 5. Develop the economic case for sustainable investment to take into account the requirements of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions. 29. An economic case for sustainable investment in new medicines, diagnostic tools, vaccines and other preventions and/or interventions prepared The investment required for implementation of the national action plan has been assessed, and plans to secure and use the required financing have been prepared Participation in international collaboration, based on fair and equitable benefitsharing as mutually agreed, in the investigation of natural sources of biodiversity and bio-repositories as sources of new antimicrobial agents Strengthening existing and creating new public private partnerships for encouraging research and developing new antimicrobial agents, vaccines and diagnostics Pilot testing of innovative ideas for financing research and development and for new market models to encourage investment and ensure access to new antimicrobial products 28

Pan-Canadian Framework and Approach to Antimicrobial Resistance Presentation to the TATFAR Policy Dialogue September 27, 2017 PURPOSE Purpose To provide TATFAR members with an overview of Canada s coordinated

Antimicrobial Resistance, yes we care! The European Joint Action Context of the Joint Action General objectives Inclusive governance Conclusion Context of the Joint Action 1. Context of this Joint Action

Jaipur Declaration on Antimicrobial Resistance We, the Health Ministers of Member States of the WHO South-East Asia Region participating in the Twenty-ninth Health Ministers Meeting in Jaipur, India, appreciate

EU strategy to fight against Antimicrobial Resistance OECD workshop on the Economics of Antimicrobial Use in the Livestock Sector and Development of Antimicrobial Resistance Paris, 12 October 2015 Martial

The Third OIE Global Conference on Veterinary Education and the Role of the Veterinary Statutory Body was held in Foz do Iguaçu (Brazil) from 4 to 6 December 2013. The Conference addressed the need for

Dr Rachid Bouguedour OIE Representative for North Africa OIE mission in the framework of One Health Focus on antimicrobial resistance (AMR) General Assembly of REEV-Med Hammamet, Tunisia 13 December 2017

OIE Strategy for Veterinary Products and Terms of Reference for the OIE National Focal Points Dr Elisabeth Erlacher-Vindel, Deputy Head of the Scientific and Technical Department OIE Strategy for Veterinary

Antimicrobial Stewardship: The South African Perspective Precious Matsoso Director General; National Department of Health; South Africa 13 th November 2015 Why do we need an AMR strategy and implementation

GHSA Meeting on Step towards Regional Strategic Collaboration in Asia-Pacific on Workforce Development, National Laboratory System Strengthening and Antimicrobial Resistance Prevention to Respond to Global

Veterinary Statutory Bodies: Their roles and importance in the good governance of Veterinary Services Regional Seminar on Veterinary Statutory Bodies in the Eastern European countries context 12-13 December

Options for a global development and stewardship framework to combat AMR Consultation of Member States and relevant partners Geneva, 29 February 2016 Peter Beyer Resolution WHA68.7 Requests the to develop

Control and monitoring of the use of antibiotics as a strategy against antimicrobials resistance Christiane Santiago Maia ANVISA - Brazilian Health Regulatory Agency s Context The burden of deaths from

OIE Standards on Animal Welfare, and Capacity Building Tools and Activities to Support their Implementation Workshop on animal welfare Organized by EC/TAIEX in co-operation with the RSPCA and State Veterinary

Antimicrobial stewardship in Canadian agriculture and veterinary medicine Perspectives from the Ad-Hoc Committee World Health Organization Antimicrobial resistance is a global crisis and needs global approach

of Conferences of OIE Regional Commissions organised since 1 June 2013 endorsed by the Assembly of the OIE on 29 May 2014 2 12 th Conference of the OIE Regional Commission for the Middle East Amman (Jordan),

JANUARY 2018 COPING WITH ANTIMICROBIAL RESISTANCE REPORT 2 Friends of Europe January 2018 This is truly a global problem that can only be addressed by working together across the planet Tamsin Rose Senior

COUNCIL OF THE EUROPEAN UNION Council Conclusions on Antimicrobial Resistance (AMR) 2876th EMPLOYMT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS Council meeting Luxembourg, 10 June 2008 The Council adopted

Strategic and Technical Advisory Group on Antimicrobial Resistance (STAG-AMR) Report of Second Meeting 14-16 April 2014 WHO Headquarters, Geneva PANDEMIC AND EPIDEMIC DISEASES WHO/HSE/PED/AIP/2014.4 Strategic

Antimicrobial stewardship Magali Dodemont, Pharm. with the support of Wallonie-Bruxelles International WHY IMPLEMENT ANTIMICROBIAL STEWARDSHIP IN HOSPITALS? Optimization of antimicrobial use To limit the

Dr Gardner Murray, Special Adviser World Organisation for Animal Health (OIE) OIE activities on rabies: PVS, vaccine banks and the OIE twinning OIE Global Conference on Rabies Control: with the support

EXTENSION PROGRAMMES DEDICATED TO THE ACTIVITIES OF THE VETERINARY SERVICES G. Khoury International Consultant 1 Original: English Summary: Extension programmes could be defined as the dissemination of

Antimicrobial resistance Summary of OIE Activities July 2015 EDITORIAL Risks associated with the use of antimicrobials in animals worldwide Dr Vallat, Director General of the World Organisation for Animal

Below please find the IDSA response to the Joint Commission s Proposed Standard for Antimicrobial Stewardship in various types of facilities, (AHC, CAH,HAP, NCC, and OBS). Comments are broken out by the

2 nd Joint Conference on the Antimicrobial Resistance Action Plan (AMRAP) and the Strategy for the Control of Antimicrobial Resistance in Ireland (SARI) 1. Background Antibiotic stewardship Implementing

7 December 2017 Committee for Medicinal Products for Veterinary Use (CVMP) Committee for Medicinal Products for Veterinary Use (CVMP) Work Plan 2018 Chairpersons Chair: D. Murphy Status Adopted in December

Veterinary Legislation and Animal Welfare Tania Dennison and David M. Sherman Objectives of the Presentation Part 1 Brief background on the OIE Veterinary Legislative Support Program (VLSP) in the context

Global Conference on Rabies Control: Towards Sustainable Prevention at the Source Seoul (Republic of Korea), 7-9 September 2011 T he World Organisation for Animal Health (OIE) is committed to supporting

Report on the Consultative meeting on antimicrobial resistance for countries in the Eastern Mediterranean Region: from policies to action Sharm El Sheikh, Egypt 12 14 November 2013 Report on the Consultative

Impact of NHS England Quality Indicators on Antimicrobial Resistance Professor Alan Johnson National Infection Service Public Health England A Risk Assessment of Antibiotic Pan-Drug Resistance in the UK:

Monitoring gonococcal antimicrobial susceptibility The rapidly changing antimicrobial susceptibility of Neisseria gonorrhoeae has created an important public health problem. Because of widespread resistance

Office International des Épizooties World Organisation for Animal Health created in 1924 in Paris The Challenge of International Biosecurity and the OIE Standards and Actions Meeting of the State Parties

OIE Collaborating Centre for Animal Welfare Science and Bioethical Analysis An innovative, multi-centre partnership between the New Zealand and Australian Governments and internationally recognised research

FMM/RAS/298: Strengthening capacities, policies and national action plans on prudent and responsible use of antimicrobials in fisheries Final Workshop in cooperation with AVA Singapore and INFOFISH 12-14

Mariano Ramos Chargé de Mission OIE Programmes Department Introductory presentation Regional Table Top Exercise for Countries of Middle East and North Africa Tunisia; 11 13 July 2017 Welcome to the Regional

Antimicrobial Use and Antimicrobial Resistance in Relation to the Canadian Pork Sector Presented by Jorge Correa Pork Committee Banff May 2013 Part of the Slides were extracted from a Paul Dick presentation